Home Newsfeeds Needham Maintains Buy on Nutanix, Raises Price Target to $31

Needham Maintains Buy on Nutanix, Raises Price Target to $31

Needham analyst Mike Cikos maintains Nutanix (NASDAQ:NTNX) with a Buy and raises the price target from $25 to $31.

byBenzinga Newsdesk

October 17, 2022

1 minute read

Needham analyst Mike Cikos maintains Nutanix (NASDAQ:NTNX) with a Buy and raises the price target from $25 to $31.

IBM Says Still Expects 2022 Constant Currency Revenue Growth At High End Of Mid-Single Digit Model; Says ‘ mid-July 2022 foreign exchange rates, currency is expected to be about a six-point headwind.’

By Bill Haddad

July 18, 4:10 PM

Full-Year 2022 Expectations Revenue growth: The company continues to expect constant currency revenue growth at the high end of its mid-single digit model. The company also expects an additional 3.5 point contribution

IBM

Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI As Preferred Category 1 Regimen For First-Line Treatment Of Cancer Of The Nasopharynx

By Benzinga Newsdesk

December 11, 9:36 AM

– NCCN Guidelines recommend LOQTORZI as the only Preferred Category 1 treatment option in first-line treatment for adults with metastatic or recurrent locally advanced NPC in combination with chemotherapy; LOQTORZI

CHRS